Bonus Biogroup

Bonus Biogroup ROA

The Return on Assets (ROA) of Bonus Biogroup (BONS.TA) as of Nov 21, 2026 is -158.60 %. In the previous year, Return on Assets (ROA) was -118.88 % — a change of 33.41% (lower).

ROA

-158.60 %

YoY

33.41%

Last updated:

In 2025, Bonus Biogroup's return on assets (ROA) was -158.60 %, a 33.41% increase from the -118.88 % ROA in the previous year.

The Bonus Biogroup ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-184.44 ILS
Jan 1, 2019
-318.17 ILS
Jan 1, 2020
-42.81 ILS
Jan 1, 2021
-86.34 ILS
Jan 1, 2022
-51.87 ILS
Jan 1, 2023
-63.55 ILS
Jan 1, 2024
-118.88 ILS
Jan 1, 2025
-158.60 ILS
The Bonus Biogroup ROA history
YEARROAYoY
-158.60 %+33.41%
-118.88 %+87.06%
-63.55 %+22.52%
-51.87 %-39.92%
-86.34 %+101.68%
-42.81 %-86.54%
-318.17 %+72.51%
-184.44 %-49.07%
-362.15 %-34.64%
-554.07 %+136.96%
-233.83 %-5.63%
-247.78 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bonus Biogroup Stock analysis

What does Bonus Biogroup do? The Bonus Biogroup Ltd is a biotechnology company based in Israel that specializes in the development and marketing of innovative medical products and therapies based on human bone marrow stem cells. The company was founded in 2008 by a group of scientists, doctors, and entrepreneurs who came together to explore and develop new approaches in regenerative medicine. The business model of Bonus Biogroup is based on utilizing the benefits of stem cells for tissue and organ regeneration. Mesenchymal stem cells (MSC), derived from bone marrow, play an important role in this process. These stem cells have the ability to differentiate into various cell types and have anti-inflammatory properties. Bonus Biogroup aims to utilize MSC technology for the development of innovative medical products and therapies to help patients with serious diseases. The company is divided into several business areas, each offering its own products and services. A key area is the development of implants and other medical devices coated with bone marrow stem cells. These products are intended to promote tissue regeneration in the body, particularly in the treatment of bone and cartilage defects and joint diseases. An example is the BioGrip implant, used in patients with osteoporosis to prevent or reduce bone fractures. Another business area of Bonus Biogroup is the production and marketing of cell therapies. In this process, mesenchymal stem cells are obtained from the patient's bone marrow and processed in a special procedure. The stem cells are then directly injected into the affected area to promote tissue regeneration. These cell therapies are used in patients with rheumatism, arthritis, joint pain, or spinal problems. In addition to research and development of new products and therapies, Bonus Biogroup also operates a large stem cell bank. This bank collects and stores human bone marrow from donors for later use in the production of implants and cell therapies. The stem cell bank is a crucial part of the business model, as it ensures a consistent and high-quality supply of mesenchymal stem cells. In summary, Bonus Biogroup is an innovative biotechnology company specializing in the use of human bone marrow stem cells. The business model is based on the development and marketing of implants, cell therapies, and other medical devices to promote tissue regeneration in the body. The company also operates a large stem cell bank to ensure a consistent supply of high-quality mesenchymal stem cells. The company has the potential to become a significant player in regenerative medicine, making a valuable contribution to improving the health and quality of life of patients. Bonus Biogroup is one of the most popular companies on Eulerpool.

ROA Details

Understanding Bonus Biogroup's Return on Assets (ROA)

Bonus Biogroup's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Bonus Biogroup's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Bonus Biogroup's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Bonus Biogroup’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Bonus Biogroup stock

Return on Assets (ROA) of Bonus Biogroup is -158.60 % in 2025.

Return on Assets (ROA) of Bonus Biogroup changed from -118.88 % to -158.60 %, representing a 33.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Bonus Biogroup since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Bonus Biogroup with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Bonus Biogroup

All Key Metrics — Bonus Biogroup